We studied the antirhinovirus activity of soluble intercellular adhesion molecule-1 (sIC.6,M-1) against all 100 numbered human rhinovirus (HRV) serotypes in human embryonic lung fibroblast (HEl) cells. sICAM-1 inhibited replication of 88 of 90 HRVs belonging to the major receptor group with 50% tt~ective concentrations (EC so ) ranging from 0.1 to 4,':{~J.Lg mr ' (-0.002 to 0.8J.LM). No inhibition at 100J.Lg l rnl" (~2J.LM) was observed for HRV belonging to the minor receptor group, type 87, and two serotypes of the major receptor group (types 23 and 25). Yield reduction assays done with five HRV serotypes in human adenoid explants found that sICAM-1 had concentrationdependent inhibitory effects that correlated closely with the activity observed in HEl cells (r2 = 0.99, P < 0.001).
Introduction
Intercellular adhesion molecule type 1 (ICAM-1) is the cell receptor for the major receptor group of human rhinoviruses (HRVs) (Greve et al., 1989; Staunton et al., 1989; Tomassini et al., 1989) . Molecules that interfere with virus-receptor interaction, such as soluble forms of ICAM-1 (sICAM-1) and anti-ICAM-1 monoclonal antibodies (mAb), can inhibit infection by major receptor group HRVs in vitro (Colonno et al., 1986; Sperber and Hayden et et., 1989; Marlin et al., 1990; Uncapher et aI., 1991) . The anti-rhinovirus activity of sICAM-1 is present during the initial stages of the infectious cycle (Marlin et aI., 1990; Greve et al., 1991; Arruda et aI., 1992) .
We have reported previously on the in vitro antirhinovirus activity of sICAM-1 for 11 major receptor group HRV serotypes in human embryonic lung (HEL) fibroblast cells (W1-38 strain) and for one serotype (HRV39) in explants of human adenoid epithelium (Arruda et st., 1992) . In this Received 4 January, 1993; revised and accepted 23 February, 1993. 'For correspondence. Tel. +804924 5059. Fax. +804 924 9065. report we extend the studies of anti-rhinovirus activity of sICAM-1 to include all 100 numbered HRV serotypes and to assess the correlation of its inhibitory effects in HEL cells and in explants of human respiratory epithelium for five HRV serotypes.
Results

Spectrum of anti-rhinoviral activity in HEL
All human rhinoviruses that belong to the major receptor group, a total of 90 numbered serotypes and one unnumbered strain, were inhibited by sICAM-1 in mono layers of HEL (W1-38) fibroblast cells, except for serotypes 23 and 25. The EC so values for the susceptible serotypes ranged between 0.1 and 41.1 J.Lg mr' (-0.002-0.8J.LM) (Table 1) .
For 77 of the numbered major receptor group serotypes (86%), EC so values were lower than 10 J.Lg mr' (~0.2 J.LM).
The EC so was ';;;1.0J.Lg rnr' (,;;; -0.02 J.LM) for 29% ofthe 90 major group serotypes (Table 1) . All 10 serotypes belonging to the minor receptor group and serotype 87, which belongs to neither the major nor minor receptor groups (Uncapher et el., 1991) were not inhibited at 100 J.Lg rnl" (-2 J.LM) of sICAM-1. Pirodavir, 0.1 J.Lg mr', inhibited the CPE of 87 (85%) of HRV serotypestotally and eight serotypes (HRV 18, 31, 41, 49, 57, 62, 78, and 99) partially (25 to 75% reduction in CPE).Seven serotypes (HRV8, 25, 45, 48, 87, 93, and 95) were not inhibited at this concentration.
Two serotypes (HRV 23 and 25), previously reported to be in the major receptor group (Uncapher et al., 1991) , were not inhibited by sICAM-1 at 100J.Lg rnr' (~2J.LM).
These results were confirmed with newly ordered aliquots of both serotypes, each obtained from two different sources deposited with ATCC (Rockville, MO). In addition, monoclonal antibody (mAb) R6.5 at 100 J.Lg mr', a concentration which totally inhibited CPE by HRV 39, was not inhibitory for any of the four viruses representing the two serotypes in either WI-38 HEL fibroblasts or HeLa cells. Serotype 23 from both ATCC sources was inhibited but type 25 was not inhibited by pirodavir at 0.1 J.Lg rnl"".
Effect of virus inoculum on EC so
The EC so values were determined for two selected major HRV serotypes (39 and 21) by CPE inhibition assays over a broad range of virus concentrations (Table 2) . Compared to the EC so values observed with very low inocula «32 TCID so per monolayer), the values increased only 5-fold for HRV-39 and 1~)-fold for HRV-21 at 1DO-fold or greater virus inputs. These results indicate that the wide range of sICAM-1 susceptibilities observed (Table 1 ) did not simply reflect differences in inoculum.
Yield reduction in adenoid explants
As previously described (Winther et al., 1990) , the epithelium grown from adenoid explants did not show visible CPE or cessation of the ciliary beating when inoculated with rhinovirus. The yields of HRV 64, 13, and 39 were reduced in the presence of sICAM-1 in a concentrationdependent fashion (Table 3) . As expected, HRV-29 was not affected by the highest concentration of sICAM-1 tested, 1OQ J.Lg ml! (-2 J.LM). In addition, HRV-23 was not inhibited by 100 J.Lg ml" of sICAM-1. We were not able to test HRV-25 in this system because of poor growth characteristics. Figure 1 shows the relationship between inhibition by sICAM-1 in the HEL microtitre assay and in the adenoid explants. The EC so values of sICAM-1 for five HRV serotypes, determined by yield reduction in adenoid explants, and the EC so values, determined by CPE inhibition in HEL fibroblasts, correlated significantly by linear regression analysis (? = 0.99, P < 0.001). In general, the EC so values obtained in adenoid explants were similario the EC so values in WI-38 HEL fibroblasts. Results expressed as mean ± SD values of 11 (HRV-39) and 2 (HRV-21) independent assays. ,,%f "The ECgo value determined with a broader range of concentrations was 1.6 fL9 rnr' in previous experiments (Arruda et sl., 1992) .
In addition, conformational changes impinging on neighbouring peptides upon docking of capsid-binding agents into the VP1 hydrophobic pocket may create steric hindrances that affect binding affinity (Pevearet al., 1989 ). Therefore, it is possible that interactions between residues on the canyon contour of certain HRV serctypes and Fig. 1 . Correlation between sICAM-1 ECgo determined in human adenoid explants by yield reduction and sICAM-1 EC so determined in HEL (W1-38 strain) cells by CPE inhibition for HRV-39, 64,13,23, and 29. Two points are indicated for type 39. ECgo values for HRV-39 were found to be 1.6 fL9 mr ' in earlier studies (Arruda et et., 1992) and to be <1.0 fLg mr ' These findings confirm and extend our earlier findings regarding the serotype-dependent inhibitory effect of sICAM-1 (Arruda et al., 1992) . In the human embryonic lung (HEL) cell microtitre assay, the EC so values ranged approximately 400 fold for major receptor group viruses. However, because of the high molecular weight of sICAM-1, the corresponding molar concentrations of sICAM-1 were relatively low (~0.002-0.8 J.LM) for these viruses. Our findings in the human adenoid epithelium outgrowth assay confirm the varying in vitro sensitivity of rhinoviruses to sICAM-1 inhibition and suggest that studies in the HEL microtitre system, which are much less labour intensive and do not require primary human tissue, predict accuratelythe antiviral activity of sICAM-1 in human respiratory epithelium in vitro.
The reasons for the broad range of susceptibility to sICAM-1 among major receptor group viruses are not certain. It has been demonstrated that although the HRV binding region comprises the N-terminal domain of ICAM-1 (McClelland et al., 1991) , a more extensive area comprising the second domain of ICAM-1 may be secondarily involved in binding (Giranda et al., 1990; . There is in direct evidence that complex quaternary protein structure interactions may be involved in the HRV attachment site (Rossmann, 1989) . For example, slight conformational changes induced by sitedirected mutagenesis in residues related to receptor binding alter the binding phenotype (Colonno et aI., 1988) .
Discussion different domains of ICAM-1 define the accessibility of sICAM-1 to the binding region.
Recently, it has been demonstrated also that there are marked serotype-dependent differences in sensitivity to the uncoating effect mediated by sICAM-1 and in receptor binding affinity (Hoover-Litty and Greve, 1993) . These workers found that incubation of HRV 14 and HRV 3, but not HRV 16, with sICAM-1 resulted in production of empty capsids, and that for these three serotypes the rate of uncoating appeared to be inversely related to virus affinity for its receptor. In our studies HRV 16 was approximately 8-fold and 14-fold more susceptible to sICAM-1 inhibition than HRV 14 and 3, respectively, in cell culture (Table 1) . We have found also that sICAM-1 did not inactivate directly HRV 39, a virus which is readily inhibited by sICAM-1 in CPE-inhibition assays in cell cultures and yield-reduction assays in human adenoid explants (Arruda, et al., 1992) . Therefore, varying receptor affinities, perhaps more than receptor-mediated uncoating, may explain serotype-dependent variability in susceptibility to sICAM-1 inhibition in cell culture among major receptor group rhinoviruses.
HRVserotypes 23 and 25, which have been classified as belonging to the major receptor group (Uncapher et aI., 1991) were not inhibited by sICAM-1 or a receptor-blocking mAb or, in the case of HRV 23, by sICAM-1 in adenoid explants. Other investigators have shown that a receptorblocking monoclonal antibody had inhibited replication of these two serotypes in HeLa cells (Uncapher et aI., 1991) . The viruses used by those investigators were obtained from the same source (ATCC), but the monoclonal antibodies differed and our studies were performed in both HEL and HeLa cells. Thus, our findings raise the possibility that HRV 23 and 25 may use an alternative cell receptor to initiate infection.
In conclusion, 89 major receptor group HRV serotypes (88 numbered and one unnumbered) were inhibited by sICAM-1 in HEL cells, and for 86% of numbered serotypes EC so values were lower than 10[1g ml" (~0.2[1M) . In contrast, two other major receptor-group viruses, HRV23 and HRV 25, were not inhibited by sICAM-1 or by anti-ICAM-1 monoclonal antibody. For a selected group of five serotypes, the inhibitory concentrations in HEL cells were comparable to those found in human adenoid explants.
Materials and Experimental procedures
Viruses, cells and reagents
All viruses were obtained from ATCC (Rockville, MD), except for the unnumbered strain HRV-Hank's, which was provided by Dr J.M. Gwaltney, Jr. Stocks were grown in HEL (W1-38 strain) fibroblasts purchased from Whittaker Bioproducts (Walkersville, MD), and most serotypes were tested after one passage. HeLa R19 cells were originally a gift from Richard Colonno (Merck Sharp and Dohme, West Point, PAl. The explant outgrowths from adenoids collected from children undergoing adenoidectomy were prepared as previously described (Andries et al., 1988; Winther et al., 1990; Arruda et al., 1992) .sICAM-1 and anti-ICAM-1 mAb R6.5, prepared and purified as previously described (Rothlein et al., 1988; Marlin et al., 1990) , were kindly furnished by Boehringer Ingelheim Pharmaceuticals (Ridgefield, CI). Pirodavir was provided by Janssen Research Foundation (Beerse, Belgium).
CPE inhibition assay in HEL
The 50% effective inhibitory concentration of sICAM-1 (EC so ), was determined in CPE inhibition assay in 96-well microtitre plates planted with WI-38 cells as previously described (Andries et al., 1988; Arruda et al., 1992) with minor modifications. The concentrations of sICAM-1 (1 fL9 mr"~20nM) ranged in 0.510g 10 dilutions from 0.1 to 100 fL9 ml-1. The test was read when the virus control showed 80-100% CPE and when the backtitre indicated that the inoculum contained 32-320 TCID so • For almost all serotypes the endpoints were determined on days 3 or 4 after inoculation. Pirodavir was used as a control in the CPE inhibition assays at 0.1 fL9 ml-1 for all serotypes.
The receptor-specificity of serotypes 23 and 25 was tested in CPE inhibition assays with mAb R6.5. For that assay quadruplicate monolayers of WI-38 HEL fibroblast or HeLa R19 cells in 96-well microtitre plates were incubated with HRV23 or25 (~1 00 TCIDso) combined with mAb R6.5 in 0.5 10glO dilutions ranging from 0.32 to 100 fL9 mr" for 1h at 34 "C. The test was read when virus control showed 80-100% CPE. HRV 39 was used as a positive control.
Yield reduction assays
Yield reduction assays were performed in adenoid explants as previously described (Arruda et et., 1992) with minor modifications. Two orthree wells of epithelial outgrowths were exposed to 180-3200 TCID so of five representative HRV serotypes at sICAM-1 concentrations of 100, 32, 10, 3.2, and 1 fL9 rnr'. The supernatants were harvested at 48h, pooled, and serial log10 dilutions were titrated in quadruplicate in WI-38 monolayers. HRV-39, a serotype of the major receptor group which is inhibited by sICAM-1 in adenoid explants (Arruda et al., 1992) ,was used as a positive control in all yield reduction assays with sICAM-1 concentrations of 1.0 and 10 fLg rnr". HRV-29, a minor group serotype not inhibited by sICAM-1 at 100 fL9 rnr', was used as a negative control.
